Chief development officer

Colin Kerr

Posted: Thursday, December 3, 2020

Oculis has appointed David Jacobs MD as Chief Development Officer.

A company spokesperson said Dr Jacobs will be based in Oculis’ newly-established US office. In his new role, he will be responsible for leading all development plans and achieving market authorisations by coordinating all regulatory activities required for future New Drug Application submissions to the US Food and Drug Administration (FDA), and the equivalent for regulators in other territories.